Published: November 2017 | Report Code: 10823 | Available Format: PDF | Pages: 161
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Technology
1.3.2 Market Segmentation by Technique
1.3.3 Market Segmentation by Application
1.3.4 Market Segmentation by Geography
1.3.5 Analysis Period
1.3.6 Market Data Reporting Unit
1.3.6.1 Value
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By region
2.2.1.2 By industry participant
2.2.1.3 By company type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Assumptions for the Study
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Technology
4.1.1.1 NGS
4.1.1.2 QPCR
4.1.1.3 IHC
4.1.1.4 ISH
4.1.1.4.1 FISH
4.1.1.4.2 CISH
4.1.1.5 Microarray
4.1.2 By Technique
4.1.2.1 Genomics
4.1.2.2 Proteomics
4.1.2.3 Epigenetics
4.1.2.4 Metabolomics
4.1.3 By Application
4.1.3.1 Personalized medicine
4.1.3.2 Diagnostics
4.1.3.3 Biomarker discovery
4.1.3.4 Prognostics
4.1.3.5 Others
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Increasing number of new cancer cases
4.2.1.2 Rising utility of biomarkers in tumor profiling
4.2.1.3 Rise in availability of funding for cancer research
4.2.1.4 Increasing demand for next generation sequencing for cancer profiling
4.2.1.5 Impact analysis of drivers on market forecast
4.2.2 Restraints
4.2.2.1 High capital investments and low benefit ratio for biomarkers
4.2.2.2 Dearth of skilled professionals and infrastructure
4.2.2.3 Impact analysis of restraints on market forecast
4.2.3 Opportunities
4.2.3.1 Increasing use of point-of-care diagnostic tests
4.2.3.2 Rising demand for personalized medicine
4.3 Porter’s Five Forces Analysis
4.3.1 Bargaining Power of Buyers
4.3.2 Bargaining Power of Suppliers
4.3.3 Intensity of Rivalry
4.3.4 Threat of New Entrants
4.3.5 Threat of Substitutes
Chapter 5. Global Market Size and Forecast
5.1 By Technology
5.1.1 ISH Technology by Type
5.2 By Technique
5.3 By Application
5.4 By Region
Chapter 6. North America Market Size and Forecast
6.1 By Technology
6.2 By Technique
6.3 By Application
6.4 By Country
Chapter 7. Europe Market Size and Forecast
7.1 By Technology
7.2 By Technique
7.3 By Application
7.4 By Country
Chapter 8. Asia-Pacific Market Size and Forecast
8.1 By Technology
8.2 By Technique
8.3 By Application
8.4 By Country
Chapter 9. LATAM Market Size and Forecast
9.1 By Technology
9.2 By Technique
9.3 By Application
9.4 By Country
Chapter 10. MEA Market Size and Forecast
10.1 By Technology
10.2 By Technique
10.3 By Application
Chapter 11. Global Market Size and Forecast by Technology
11.1 Global NGS Market, by Region
11.2 Global QPCR Market, by Region
11.3 Global IHC Devices Market, by Region
11.4 Global ISH Market, by Region
11.5 Global Microarray Market, by Region
Chapter 12. Global Market Size and Forecast by Technique
12.1 Global Genomics Market, by Region
12.2 Global Proteomics Market, by Region
12.3 Global Epigenetics Devices Market, by Region
12.4 Global Metabolomics Market, by Region
Chapter 13. Global Market Size and Forecast by Application
13.1 Global Personalized Medicine Market, by Region
13.2 Global Diagnostics Market, by Region
13.3 Global Biomarker Discovery Market, by Region
13.4 Global Prognostics Market, by Region
Chapter 14. Competitive Landscape
14.1 Product Benchmarking of Key Players
14.2 Global Strategic Developments of Key Players
14.2.1 Product Launches and Approvals
14.2.2 Agreements, Partnerships and Collaborations
14.2.3 Facility Expansion
14.2.4 Other Developments
Chapter 15. Company Profiles
15.1 Illumina, Inc.
15.1.1 Business Overview
15.1.2 Product and Service Offerings
15.1.3 Key Financial Summary
15.1.4 Strategic Growth Plans
15.2 NeoGenomics Inc.
15.2.1 Business Overview
15.2.2 Product and Service Offerings
15.2.3 Key Financial Summary
15.2.4 Strategic Growth Plans
15.3 Caris Life Sciences, Inc.
15.3.1 Business Overview
15.3.2 Product and Service Offerings
15.3.3 Strategic Growth Plans
15.4 QIAGEN N.V.
15.4.1 Business Overview
15.4.2 Product and Service Offerings
15.4.3 Key Financial Summary
15.4.4 Strategic Growth Plans
15.5 Helomics Corp.
15.5.1 Business Overview
15.5.2 Product and Service Offerings
15.5.3 Strategic Growth Plans
15.6 Oxford Gene Technology
15.6.1 Business Overview
15.6.2 Product and Service Offerings
15.6.3 Strategic Growth Plans
15.7 HTG Molecular Diagnostics, Inc.
15.7.1 Business Overview
15.7.2 Product and Service Offerings
15.7.3 Key Financial Summary
15.7.4 Strategic Growth Plans
15.8 RiboMed Biotechnologies, Inc.
15.8.1 Business Overview
15.8.2 Product and Service Offerings
15.8.3 Strategic Growth Plans
15.9 Genomic Health, Inc.
15.9.1 Business Overview
15.9.2 Product and Service Offerings
15.9.3 Key Financial Summary
15.9.4 Strategic Growth Plans
15.10 NanoString Technologies, Inc.
15.10.1 Business Overview
15.10.2 Product and Service Offerings
15.10.3 Key Financial Summary
15.10.4 Strategic Growth Plans
Chapter 16. Appendix
16.1 Abbreviations
16.2 Related Report
LIST OF TABLES
TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)
TABLE 5 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)
TABLE 6 GLOBAL ISH TECHNOLOGY MARKET, BY TYPE, $M (2013 – 2016)
TABLE 7 GLOBAL ISH TECHNOLOGY MARKET, BY TYPE, $M (2017 – 2023)
TABLE 8 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)
TABLE 9 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)
TABLE 10 GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)
TABLE 11 GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)
TABLE 12 GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION, $M (2013 – 2016)
TABLE 13 GLOBAL CANCER/TUMOR PROFILING MARKET, BY REGION, $M (2017 – 2023)
TABLE 14 DIFFERENT TYPE OF CANCERS AND THE AMOUNT FUNDED
TABLE 15 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)
TABLE 16 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)
TABLE 17 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)
TABLE 18 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)
TABLE 19 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)
TABLE 20 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)
TABLE 21 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2016)
TABLE 22 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 – 2023)
TABLE 23 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)
TABLE 24 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)
TABLE 25 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)
TABLE 26 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)
TABLE 27 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)
TABLE 28 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)
TABLE 29 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2016)
TABLE 30 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 – 2023)
TABLE 31 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)
TABLE 32 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)
TABLE 33 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)
TABLE 34 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)
TABLE 35 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)
TABLE 36 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)
TABLE 37 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2016)
TABLE 38 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 – 2023)
TABLE 39 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)
TABLE 40 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)
TABLE 41 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)
TABLE 42 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)
TABLE 43 LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)
TABLE 44 LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)
TABLE 45 LATAM CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2016)
TABLE 46 LATAM CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2017 – 2023)
TABLE 47 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2016)
TABLE 48 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2017 – 2023)
TABLE 49 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2016)
TABLE 50 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2017 – 2023)
TABLE 51 MEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2016)
TABLE 52 MEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2017 – 2023)
TABLE 53 GLOBAL NGS MARKET, BY REGION, $M (2013 – 2016)
TABLE 54 GLOBAL NGS MARKET, BY REGION, $M (2017 – 2023)
TABLE 55 GLOBAL QPCR MARKET, BY REGION, $M (2013 – 2016)
TABLE 56 GLOBAL QPCR MARKET, BY REGION, $M (2017 – 2023)
TABLE 57 GLOBAL IHC DEVICES MARKET, BY REGION, $M (2013 – 2016)
TABLE 58 GLOBAL IHC DEVICES MARKET, BY REGION, $M (2017 – 2023)
TABLE 59 GLOBAL ISH MARKET, BY REGION, $M (2013 – 2016)
TABLE 60 GLOBAL ISH MARKET, BY REGION, $M (2017 – 2023)
TABLE 61 GLOBAL MICROARRAY MARKET, BY REGION, $M (2013 – 2016)
TABLE 62 GLOBAL MICROARRAY MARKET, BY REGION, $M (2017 – 2023)
TABLE 63 GLOBAL GENOMICS MARKET, BY REGION, $M (2013 – 2016)
TABLE 64 GLOBAL GENOMICS MARKET, BY REGION, $M (2017 – 2023)
TABLE 65 GLOBAL PROTEOMICS MARKET, BY REGION, $M (2013 – 2016)
TABLE 66 GLOBAL PROTEOMICS MARKET, BY REGION, $M (2017 – 2023)
TABLE 67 GLOBAL EPIGENETICS DEVICES MARKET, BY REGION, $M (2013 – 2016)
TABLE 68 GLOBAL EPIGENETICS DEVICES MARKET, BY REGION, $M (2017 – 2023)
TABLE 69 GLOBAL METABOLOMICS MARKET, BY REGION, $M (2013 – 2016)
TABLE 70 GLOBAL METABOLOMICS MARKET, BY REGION, $M (2017 – 2023)
TABLE 71 GLOBAL PERSONALIZED MEDICINE MARKET, BY REGION, $M (2013 – 2016)
TABLE 72 GLOBAL PERSONALIZED MEDICINE MARKET, BY REGION, $M (2017 – 2023)
TABLE 73 GLOBAL DIAGNOSTICS MARKET, BY REGION, $M (2013 – 2016)
TABLE 74 GLOBAL DIAGNOSTICS MARKET, BY REGION, $M (2017 – 2023)
TABLE 75 GLOBAL BIOMARKER DISCOVERY MARKET, BY REGION, $M (2013 – 2016)
TABLE 76 GLOBAL BIOMARKER DISCOVERY MARKET, BY REGION, $M (2017 – 2023)
TABLE 77 GLOBAL PROGNOSTICS MARKET, BY REGION, $M (2013 – 2016)
TABLE 78 GLOBAL PROGNOSTICS MARKET, BY REGION, $M (2017 – 2023)
TABLE 79 ILLUMINA, INC. – AT A GLANCE
TABLE 80 ILLUMINA, INC. – KEY FINANCIAL SUMMARY
TABLE 81 NEOGENOMICS INC.– AT A GLANCE
TABLE 82 NEOGENOMICS INC. – KEY FINANCIAL SUMMARY
TABLE 83 CARIS LIFE SCIENCES, INC.– AT A GLANCE
TABLE 84 QIAGEN N.V. – AT A GLANCE
TABLE 85 QIAGEN N.V. – KEY FINANCIAL SUMMARY
TABLE 86 HELOMICS CORP. – AT A GLANCE
TABLE 87 OXFORD GENE TECHNOLOGY – AT A GLANCE
TABLE 88 HTG MOLECULAR DIAGNOSTICS, INC. -AT A GLANCE
TABLE 89 HTG MOLECULAR DIAGNOSTICS, INC. – KEY FINANCIAL SUMMARY
TABLE 90 RIBOMED BIOTECHNOLOGIES, INC. - AT A GLANCE
TABLE 91 GENOMIC HEALTH, INC. - AT A GLANCE
TABLE 92 GENOMIC HEALTH, INC. – KEY FINANCIAL SUMMARY
TABLE 93 NANOSTRING TECHNOLOGIES, INC. – AT A GLANCE
TABLE 94 NANOSTRING TECHNOLOGIES, INC., – KEY FINANCIAL SUMMARY
LIST OF FIGURES
FIG 1 RESEARCH METHODOLOGY
FIG 2 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY REGION
FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
FIG 6 DATA TRIANGULATION APPROACH
FIG 7 GLOBAL CANCER/TUMOR PROFILING MARKET SUMMARY
FIG 8 PORTER’S FIVE FORCES ANALYSIS
FIG 9 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)
FIG 10 GLOBAL ISH TECHOLOGY MARKET, BY TYPE, $M (2013 – 2023)
FIG 11 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)
FIG 12 GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)
FIG 13 WORLDWIDE MAJOR MARKETS FOR CANCER/TUMOR PROFILING
FIG 14 NORTH AMERICA CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIG 15 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)
FIG 16 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)
FIG 17 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)
FIG 18 NORTH AMERICA CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2023)
FIG 19 EUROPE CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIG 20 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)
FIG 21 EUROPE CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)
FIG 22 EUROPE CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)
FIG 23 EUROPE CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2023)
FIG 24 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIG 25 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)
FIG 26 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)
FIG 27 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)
FIG 28 ASIA-PACIFIC CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2023)
FIG 29 LATAM CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIG 30 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)
FIG 31 LATAM CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)
FIG 32 LATAM CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)
FIG 33 LATAM CANCER/TUMOR PROFILING MARKET, BY COUNTRY, $M (2013 – 2023)
FIG 34 MEA CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIG 35 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, $M (2013 – 2023)
FIG 36 MEA CANCER/TUMOR PROFILING MARKET, BY TECHNIQUE, $M (2013 – 2023)
FIG 37 MEA CANCER/TUMOR PROFILING MARKET, BY APPLICATION, $M (2013 – 2023)
FIG 38 GLOBAL NGS MARKET, BY REGION, $M (2013 – 2023)
FIG 39 GLOBAL QPCR MARKET, BY REGION, $M (2013 – 2023)
FIG 40 GLOBAL IHC DEVICES MARKET, BY REGION, $M (2013 – 2023)
FIG 41 GLOBAL ISH MARKET, BY REGION, $M (2013 – 2023)
FIG 42 GLOBAL MICROARRAY MARKET, BY REGION, $M (2013 – 2023)
FIG 43 GLOBAL GENOMICS MARKET, BY REGION, $M (2013 – 2023)
FIG 44 GLOBAL PROTEOMICS MARKET, BY REGION, $M (2013 – 2023)
FIG 45 GLOBAL EPIGENETICS DEVICES MARKET, BY REGION, $M (2013 – 2023)
FIG 46 GLOBAL METABOLOMICS MARKET, BY REGION, $M (2013 – 2023)
FIG 47 GLOBAL PERSONALIZED MEDICINE MARKET, BY REGION, $M (2013 – 2023)
FIG 48 GLOBAL DIAGNOSTICS MARKET, BY REGION, $M (2013 – 2023)
FIG 49 GLOBAL BIOMARKER DISCOVERY MARKET, BY REGION, $M (2013 – 2023)
FIG 50 GLOBAL PROGNOSTICS MARKET, BY REGION, $M (2013 – 2023)
FIG 51 ILLUMINA, INC. – REVENUE SPLIT BY GEOGRAPHY (2016)
FIG 52 NEOGENOMICS INC. – REVENUE SPLIT BY SEGMENT (2016)
FIG 53 QIAGEN N.V. - REVENUE SPLIT BY GEOGRAPHY (2016)
FIG 54 HTG MOLECULAR DIAGNOSTICS, INC. – REVENUE SPLIT BY PRODUCT (2016)
FIG 55 HTG MOLECULAR DIAGNOSTICS, INC. – REVENUE SPLIT BY SERVICES (2016)
FIG 56 GENOMIC HEALTH, INC. – REVENUE SPLIT BY GEOGRAPHY (2016)
FIG 57 NANOSTRING TECHNOLOGIES, INC. - REVENUE SPLIT BY PRODUCT AND SERVICES (2016)
FIG 58 NANOSTRING TECHNOLOGIES, INC. - REVENUE SPLIT BY GEOGRAPHY (2016)
Get a bespoke market intelligence solution
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to AnalystOur dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws